CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-03 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −675 | $28.91 | $20K | 37,705 |
| 2021-02-03 | Clague Laura Chief Financial Officer | Sale | −2,500 | $28.91 | $72K | 33,348 |
| 2021-02-03 | Clague Laura Chief Financial Officer | Sale | −1,125 | $28.91 | $33K | 32,223 |
| 2021-02-03 | Dube Eric M Chief Executive Officer | Sale | −2,406 | $28.91 | $70K | 148,939 |
| 2021-02-02 | Heerma Peter Chief Commercial Officer | Sale | −563 | $30.75 | $17K | 57,657 |
| 2021-02-02 | Rosenberg Noah L. Chief Medical Officer | Sale | −1,250 | $30.75 | $38K | 46,470 |
| 2021-02-02 | Rosenberg Noah L. Chief Medical Officer | Sale | −563 | $30.75 | $17K | 45,907 |
| 2021-02-02 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −2,500 | $30.75 | $77K | 40,957 |
| 2021-02-02 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −1,125 | $30.75 | $35K | 43,457 |
| 2021-02-02 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −2,500 | $30.75 | $77K | 41,555 |
| 2021-02-02 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −675 | $30.75 | $21K | 40,880 |
| 2021-02-02 | Dube Eric M Chief Executive Officer | Sale | −6,328 | $29.60 | $187K | 153,751 |
| 2021-02-02 | Dube Eric M Chief Executive Officer | Sale | −2,406 | $30.75 | $74K | 151,345 |
| 2021-02-02 | Clague Laura Chief Financial Officer | Sale | −2,500 | $30.75 | $77K | 36,973 |
| 2021-02-02 | Clague Laura Chief Financial Officer | Sale | −1,125 | $30.75 | $35K | 35,848 |
| 2021-02-02 | ASELAGE STEVE Director | Option exercise | +25,000 | $10.09 | $252K | 221,667 |
| 2021-02-02 | ASELAGE STEVE Director | Sale | −25,000 | $30.75 | $769K | 196,667 |
| 2021-01-31 | Rosenberg Noah L. Chief Medical Officer | Grant or award | +5,000 | 47,720 | ||
| 2021-01-31 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award | +5,000 | 44,582 | ||
| 2021-01-31 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +5,000 | 44,055 |
Page 38 of 51 · 1,020 trades